1H-MRS at 4 Tesla in minimally treated early schizophrenia

Molecular Psychiatry

Volumn 15, Issue 6, 2010, Pages 629-636

  Bustillo, J R ^a,b   Rowland, L M ^c   Mullins, P ^d   Jung, R ^a,b,d   Chen, H ^a   Qualls, C ^a   Hammond, R ^a   Brooks, W M ^e   Lauriello, J ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d MIND RESEARCH NETWORK   (United States)

^e UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

1H MRS; Antipsychotic drug; Glutamate; Glutamine; NAA; Schizophrenia

Indexed keywords

CLOZAPINE; GLUTAMIC ACID; GLUTAMINE; HALOPERIDOL; N ACETYLASPARTIC ACID; QUETIAPINE; RISPERIDONE; ASPARTIC ACID; DRUG DERIVATIVE; N-ACETYLASPARTATE; NEUROLEPTIC AGENT; PROTON;

ADULT; AMINO ACID ANALYSIS; AMINO ACID DEFICIENCY; AMINO ACID METABOLISM; ARTICLE; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXCITOTOXICITY; FEMALE; HUMAN; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA; THALAMUS; TREATMENT OUTCOME; WHITE MATTER; FRONTAL LOBE; METABOLISM; METHODOLOGY; MYELINATED NERVE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; TIME;

ADULT; ANTIPSYCHOTIC AGENTS; ASPARTIC ACID; FEMALE; FRONTAL LOBE; GLUTAMIC ACID; GLUTAMINE; GYRUS CINGULI; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NERVE FIBERS, MYELINATED; PROTONS; SCHIZOPHRENIA; THALAMUS; TIME FACTORS;

EID: 77952888256     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2009.121     Document Type: Article

References (41)

1. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998-1007.
2. Farber NB, Wozniak DF, Price MT, Labruyere J, Huss J, St Peter H et al. Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia. Biol Psychiatry 1995; 38: 788-796.
3. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway for NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1992; 17: 2921-2927.
4. Reynolds LM, Cochran SM, Morris BJ, Pratt JA, Reynolds GP. Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartylglutamate in rat brain. Schizophr Res 2005; 73: 147-152.
5. Newcomer JW, Krystal JH. NMDA receptor regulation of memory and behavior in humans. Hippocampus 2001; 11: 529-542.
6. Rowland L, Bustillo J, Mullins P, Jung R, Lenroot R, Landgraf E et al. The effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4.0T proton MRS study. Am J Psychiatry 2005; 162: 394-396.
7. Theberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J et al. Glutamate and glutamine measured with 4.0T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 2002; 159: 1944-1946.
8. Chang L, Friedman J, Ernst T, Zhong K, Tsopelas ND, Davis K. Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction. Biol Psychiatry 2007; 62: 1396-1404.
9. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindström LH, Iyo M. Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug na?̈ve schizophrenic patients. BMC Psychiatry 2005; 5: 6.
10. Bustillo J, Barrow R, Paz R, Tang J, Seraji-Bozorgzad N, Moore G et al. Long term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels. Neuropsychopharmacology 2006; 31: 751-756.
11. Bartha R, Drost DJ, Menon RS, Williamson PC. Comparison of the quantification precision of human short echo time (1)H spectro-scopy at 1.5 and 4.0 Tesla. Magn Reson Med 2000; 44: 185-192.
12. 1H-MRS in vivo. Magn Reson Med 1999; 40: 193-197.
13. Petropoulos H, Sibbitt Jr WL, Brooks WM. Automated T2 quantitation in neuropsychiatric lupus erythematosus: a marker of active disease. J Magn Reson Imaging 1999; 9: 39-43.
14. Ernst T, Kreis R, Ross BD. Absolute quantitation of water and metabolites in the human brain. 1. Compartments and water. J Magn Reson B 1993; 102: 1-8.
15. Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS). University of Iowa, Iowa City, 1984.
16. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). University of Iowa, Iowa City, 1984.
17. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11-19.
18. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-676.
19. Guy W. ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. US Department of Health, Education and Welfare: Washington, DC, 1976 pp 534-537.
20. Steen RG, Hamer RM, Lieberman JA. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology 2005; 30: 1949-1962.
21. Lindquist DM, Hawk RM, Karson CN, Komoroski RA. Effects of antipsychotic drugs on metabolite ratios in rat brain in vivo. Magn Reson Med 2000; 43: 355-358.
22. Bustillo J, Wolff C, Myers-Gutierrez A, Dettmer T, Cooper T, Allan A et al. Treatment of rats with antipsychotic drugs: lack of an effect on N acetyl-aspartate levels. Schizophr Res 2002; 1889: 1-9.
23. Magistretti PJ, Pellerin L. Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Phil Trans R Soc Lond 1999; 354: 1155-1163. (Pubitemid 29400898)
24. Xu S, Yang J, Li C, Zhu W, Shen J. Metabolic alterations in focally activated primary somatosensory cortex of alpha-chloralose-anesthetized rats measured by H MRS at 11.7T. Neuroimage 2005; 28: 401-409.
25. Tibbo P, Hanstock C, Valiakalayil A, Allen P. 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am J Psychiatry 2004; 161: 1116-1118.
26. Tebartz van Elst L, Valerius G, Buchert M, Thiel T, Rusch N, Bubl E et al. Increased prefrontal and hippocampal glutamate and concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol Psychiatry 2005; 58: 724-730.
27. Theberge J, Al-Semaan Y, Williamson PC, Menon RS, Neufeld RW, Rajakumar N et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 2003; 160: 2231-2233.
28. Choe BY, Suh TS, Shinn KS, Lee CW, Lee C, Paik IH. Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. Invest Radiol 1996; 6: 345-352.
29. Fannon D, Simmons A, Tennakoon L, O'Ceallaiagh S, Sumich A, Doku Vet al. Selective deficit of hippocampal N-acetylaspartate in antipsychotic-na?̈ve patients with schizophrenia. Biol Psychiatry 2003; 54: 587-598.
30. Bustillo J, Lauriello J, Rowland L, Thomson L, Petropoulus H, Hammond R et al. Longitudinal follow-up of neurochemi-cal changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure. Schizophr Res 2002; 58: 313-321.
31. Bustillo J, Rowland L, Jung R, Brooks W, Qualls C, Hammond R et al. Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia. Neuropsychopharmacology 2008; 33: 2456-2466.
32. Theberge J, Williamson KE, Aoyama N, Drost DJ, Manchanda R, Malla AK et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br J Psychiatry 2007; 191: 325-334.
33. Baldessarini RJ, Hegarty JD, Bird ED, Benes FM. Meta-analysis of postmortem studies of Alzheimer's disease-like neuropathology in schizophrenia. Am J Psychiatry 1997; 154: 861-863.
34. Glantz L, Lewis D. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 2000; 57: 65-73.
35. Lentz M, Kim J, Westmoreland S, Greco J, Fuller R, Ratai E et al. Quantitative neuropathologic correlates of changes in ratio of N-acetylaspartate to creatine in macaque brain. Radiology 2005; 235: 461-468.
36. Hajszan T, Leranth C, Roth RH. Subchronic phencyclidine treatment decreases the number of dendritic spine synapses in the rat prefrontal cortex. Biol Psychiatry 2006; 60: 639-644.
37. Matute C, Melone M, Vallejo-Illarramendi A, Conti F. Increased expression of the astrocytic glutamate transporter GLT-1 in the prefrontal cortex of schizophrenics. Glia 2005; 49: 451-455.
38. Gluck MR, Thomas RG, Davis KL, Haroutunian V. Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients. Am J Psychiatry 2002; 159: 1165-1173.
39. López-Gil X, Babot Z, Amargós-Bosch M, Suñol C, Artigas F, Adell A. Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacol-ogy 2007; 32: 2087-2097.
40. Lim KO, Hedehus M, Moseley M, de Crespigny A, Sullivan EV, Pferfferbaum A. Proton magnetic resonance imaging of cortical gray and white matter in schizophrenia. Arch Gen Psychiatry 1998; 55: 346-352.
41. Pfefferbaum A, Sullivan EV, Hedehus M, Moseley M, Lim KO. Brain gray and white matter transverse relaxation time in schizophrenia. Psychiatry Res 1999; 91: 93-100.